“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of Alterome ...

Roche also axed a trial for divarasib, specifically a phase 2/3 trial that was comparing the KRAS G12C inhibitor to docetaxel in the second-line treatment of non-small cell lung cancer (NSCLC).

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer. These findings suggest ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...